Table 1.
T- and NK-cell biomarkers, thresholds, and clinical outcome after HSCT.
| Biomarker | Pts | Donor | Days | Statistics | Threshold | Outcome | Reference |
|---|---|---|---|---|---|---|---|
| ALC | 138 | HLA-sib | +30 | Median | >690 cells/μL | ↓TRM ↑LFS ↑OS | Montero et al. (2006) |
| 157 | HLA-sib | +30 | Median | >450 cells/μL | ↓TRM ↓RI ↑OS | Savani et al. (2007a) | |
| 102 | MUD | +30 | Arbitrary | >1000 cells/μL | ↓TRM ↑LFS ↑OS | Le Blanc et al. (2009) | |
| 65 | Haplo UCB | +60 | Arbitrary | >1000 cells/μL | ↓TRM ↑OS | Ciurea et al. (2011) | |
| 360 | UCB | +30 | From Savani et al. (2007a) | >200 cells/μL | ↓TRM ↑LFS ↑OS | Burke et al. (2011) | |
| CD4+ T cells | 69 | HLA-sib MUD | +90 | Arbitrary (HIV) | >200 cells/μL | ↓TRM ↑OS ↓infect. | Kim et al. (2006) |
| 758 | HLA-sib MUD | +35 | Median | >86 cells/μL | ↓TRM | Berger et al. (2008) | |
| 345 | HLA-sib MUD | +90 | From Matthews et al. (2010) | >200 cells/μL | ↓TRM | Buhlmann et al. (2011) | |
| 99 | HLA-sib MUD | +20 | ROC | >115 cells/μL | ↓TRM | Fedele et al. (2012) | |
| CD8+ T cells | 32 | HLA-sib MUD | +365 | Arbitrary | >V percentile | ↑OS | Koehl et al. (2007) |
| iNKT/T ratio | 71 | HLA-sib MUD | +15 | ROC | >0.58 × 10−3 | ↓aGVHD ↓TRM ↑OS | Rubio et al. (2012) |
| 22 | Haplo | +545 | Median | >10−4 | No relapse | Casorati et al. (2012) | |
| TREC values | 102 | HLA-sib | Pre-tx | Categories | 172/150,000 T | ↑OS ↓infections | Clave et al. (2005) |
| 33 | Haplo | +180 | Categories | sj < 0.1/150,000 T; β< 0.001/150,000 T |
↑RI | Clave et al. (2012) | |
| Tregs frequencies | 60 | HLA-sib MUD | aGVHD | Median | >0.5% over TNC | ↓TRM ↑OS | Magenau et al. (2010) |
| 57 | HLA-sib MUD | cGVHD | Categories | >3% over PBL | No cGVHD | Koreth et al. (2011) | |
| CMV-specific CD8+ T cells | 24 | HLA-sib MUD | +100 | Arbitrary | >10 tet+ cells/μL | No CMV disease | Cwynarski et al. (2001) |
| 83 | HLA-sib MUD | +65 | Categories | >7 tet+ cells/μL | ↓CMV disease | Gratama et al. (2010) | |
| 133 | HLA-sib MUD UCB |
+120 | Categories | >1 cyt+ cells/μL | ↓CMV DNAemia | Tormo et al. (2011) | |
| 131 | HLA-sib MUD Haplo |
+365 | ROC | >3 cyt+ cells/μL | No CMV DNAemia | Lilleri et al. (2012) | |
| CMV-specific CD4+ T cells | 30 | HLA-sib MUD | +120 | Arbitrary | >2.5 S.I. | ↓CMV disease | Krause et al. (1997) |
| 32 | HLA-sib MUD | +40 | Median | >0.4 cyt+ cells/μL | No CMV DNAemia | Pourgheysari et al. (2009) | |
| 133 | HLA-sib MUD UCB |
+120 | Categories | >1.2 cyt+ cells/μL | ↓CMV DNAemia | Tormo et al. (2011) | |
| 117 | UCB | +30 | Arbitrary | >7 S.I. | No infections ↑ LFS | Parkman et al. (2006) | |
| 131 | HLA-sib MUD Haplo |
+365 | ROC | >1 cyt+ cells/μL | No CMV DNA | Lilleri et al. (2012) | |
| EBV-specific T cells | 33 | MUD | +56 | Categories | >1 cyt+ cells/μL | No relapse | Hoegh-Petersen et al. (2012) |
| NK-cells | 43 | Haplo | +15 | Median | >9.27 cells/μL | ↑LFS | Chang et al. (2008) |
| 54 | HLA-sib | +30 | Median | >150 cells/μL | ↓TRM ↓RI ↑OS ↓aGVHD |
Savani et al. (2007b) | |
| 345 | HLA-sib MUD | +365 | From Ruggeri et al. (2002) | >150 cells/μL | ↓TRM | Buhlmann et al. (2011) |
ALC, absolute lymphocyte count; HLA-sib, HLA-identical sibling; TRM, transplant-related mortality; LFS, leukemia-free survival; OS, overall survival; RI, relapse incidence; MUD, matched unrelated donor; Haplo, HLA-haploidentical; UCB, umbilical cord-blood; ROC, receiver operating characteristic curve analysis; aGVHD, acute graft-versus-host-disease; TREC, T cell receptor excision circles; pre-tx, pre-transplant; TNC, total nucleated cells; cGVHD, chronic graft-versus-host-disease; PBL, peripheral blood lymphocytes; Tet+, tetramer-positive cells; cyt+, intracellular cytokine-positive; S.I., stimulation index.